TY - JOUR
T1 - Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia
AU - Oni-Orisan, Akin
AU - Kristiansen, Lars V.
AU - Haroutunian, Vahram
AU - Meador-Woodruff, James H.
AU - McCullumsmith, Robert E.
N1 - Funding Information:
This work was supported by a Civitan Emerging Scholar Award (LVK), MH074016 (REM), VA Merit Review (VH), MH064673 (VH), and MH53327 (JHM-W).
Funding Information:
Akin Oni-Orisan reported no biomedical financial interests or potential conflicts of interest. Lars V. Kristiansen reported no biomedical financial interests or potential conflicts of interest. Vahram Haroutunian reported no biomedical financial interests or potential conflicts of interest. Robert E. McCullumsmith reported no biomedical financial interests or potential conflicts of interest. James H. Meador-Woodruff reports that his laboratory receives grant and other financial support from National Institutes of Health (NIH), Stanley Foundation, National Alliance for Research on Schizophrenia and Depression (NARSAD), and American Psychiatric Institute for Education and Research and that he receives compensation from the American College of Neuropsychopharmacology (ACNP) as the Editor-in-Chief of Neuropsychopharmacology.
PY - 2008/4/15
Y1 - 2008/4/15
N2 - Background: Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families. An increasing number of studies have found that schizophrenia is marked by dysregulation of glutamatergic neurotransmission. While numerous studies have found alterations of postsynaptic molecules in schizophrenia, a growing body of evidence implicates presynaptic factors. Vesicular glutamate transporters (VGLUTs) have been identified and are known to package glutamate into vesicles in the presynaptic terminal for subsequent release into the synaptic cleft. Recent studies have shown that VGLUTs regulate synaptic activity via the amount of glutamate released. Accordingly, we hypothesized that VGLUTs are altered in schizophrenia, contributing to dysfunction of presynaptic activity. Methods: Using in situ hybridization and Western blot analysis, we investigated alterations in VGLUT1 and VGLUT2 transcript and protein expression in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and a comparison group. Results: We found increased VGLUT1 transcript and reduced VGLUT1 protein expression in the ACC, but not DLPFC, in schizophrenia. Vesicular glutamate transporter 2 was unchanged at both levels of gene expression. We did not find changes in VGLUT1 messenger RNA (mRNA) or protein levels following 28-day treatment of rats with haloperidol (2 mg/kg/day), suggesting that our findings in schizophrenia are not due to an effect of antipsychotic treatment. Conclusions: Overall, our data suggest decreased glutamate release in the ACC, as well as discordant regulation of VGLUT1 expression at different levels of gene expression.
AB - Background: Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families. An increasing number of studies have found that schizophrenia is marked by dysregulation of glutamatergic neurotransmission. While numerous studies have found alterations of postsynaptic molecules in schizophrenia, a growing body of evidence implicates presynaptic factors. Vesicular glutamate transporters (VGLUTs) have been identified and are known to package glutamate into vesicles in the presynaptic terminal for subsequent release into the synaptic cleft. Recent studies have shown that VGLUTs regulate synaptic activity via the amount of glutamate released. Accordingly, we hypothesized that VGLUTs are altered in schizophrenia, contributing to dysfunction of presynaptic activity. Methods: Using in situ hybridization and Western blot analysis, we investigated alterations in VGLUT1 and VGLUT2 transcript and protein expression in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and a comparison group. Results: We found increased VGLUT1 transcript and reduced VGLUT1 protein expression in the ACC, but not DLPFC, in schizophrenia. Vesicular glutamate transporter 2 was unchanged at both levels of gene expression. We did not find changes in VGLUT1 messenger RNA (mRNA) or protein levels following 28-day treatment of rats with haloperidol (2 mg/kg/day), suggesting that our findings in schizophrenia are not due to an effect of antipsychotic treatment. Conclusions: Overall, our data suggest decreased glutamate release in the ACC, as well as discordant regulation of VGLUT1 expression at different levels of gene expression.
KW - Haloperidol
KW - VGLUT1
KW - VGLUT2
KW - Western blot
KW - in situ hybridization
KW - postmortem
KW - prefrontal cortex
UR - https://www.scopus.com/pages/publications/40849086426
U2 - 10.1016/j.biopsych.2007.10.020
DO - 10.1016/j.biopsych.2007.10.020
M3 - Article
C2 - 18155679
AN - SCOPUS:40849086426
SN - 0006-3223
VL - 63
SP - 766
EP - 775
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 8
ER -